What question did this study set out to answer?

To review technological developments, clinical utilities, and translational research opportunities for circulating tumor DNA (ctDNA) profiling in B-cell lymphoma management.

June 14, 2022LeukemiaOpen Access

Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research

View Full Paper

Ask AI

Bookmark

Authors

ELEliza LauerUniversity of Freiburg JMJurik MutterStanford Medicine FSFlorian SchererUniversity of Freiburg

Discussion

Member takes

Implication

Review highlights the clinical utility of circulating tumor DNA profiling in B-cell lymphoma, indicating its potential to guide personalized therapy and monitor minimal residual disease.

Key Points

To review technological developments, clinical utilities, and translational research opportunities for circulating tumor DNA (ctDNA) profiling in B-cell lymphoma management.
Synthesized pre-analytical considerations, assay methodologies, error-suppression approaches, and sensitivity enhancements for ctDNA genotyping.
Evaluated clinical evidence regarding ctDNA utility for disease classification, monitoring treatment response, assessing tumor burden, and detecting measurable residual disease.
ctDNA assessment captures comprehensive mutational heterogeneity across multiple anatomical tumor sites, overcoming the spatial sampling limitations of traditional single-site biopsies.
Serial blood profiling facilitates real-time quantification of dynamic tumor burden, robust outcome prediction, and early detection of measurable residual disease before radiographic recurrence.
ctDNA holds utility as an emerging surrogate endpoint in clinical trials and a biomarker tool to steer risk-adapted, personalized treatment protocols.

Cite This Study

Lauer et al. (2022) studied this question.

synapsesocial.com/papers/6a7c17ecc06c4f060a75f150 https://doi.org/10.1038/s41375-022-01618-w

View Full Paper

Ask AI

Bookmark

June 14, 2022LeukemiaOpen Access

Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research

View Full Paper

Ask AI

Bookmark

Authors

ELEliza LauerUniversity of Freiburg JMJurik MutterStanford Medicine FSFlorian SchererUniversity of Freiburg

Discussion

Member takes

Implication

Review highlights the clinical utility of circulating tumor DNA profiling in B-cell lymphoma, indicating its potential to guide personalized therapy and monitor minimal residual disease.

Key Points

To review technological developments, clinical utilities, and translational research opportunities for circulating tumor DNA (ctDNA) profiling in B-cell lymphoma management.
Synthesized pre-analytical considerations, assay methodologies, error-suppression approaches, and sensitivity enhancements for ctDNA genotyping.
Evaluated clinical evidence regarding ctDNA utility for disease classification, monitoring treatment response, assessing tumor burden, and detecting measurable residual disease.
ctDNA assessment captures comprehensive mutational heterogeneity across multiple anatomical tumor sites, overcoming the spatial sampling limitations of traditional single-site biopsies.
Serial blood profiling facilitates real-time quantification of dynamic tumor burden, robust outcome prediction, and early detection of measurable residual disease before radiographic recurrence.
ctDNA holds utility as an emerging surrogate endpoint in clinical trials and a biomarker tool to steer risk-adapted, personalized treatment protocols.

Cite This Study

Lauer et al. (2022) studied this question.

synapsesocial.com/papers/6a7c17ecc06c4f060a75f150 https://doi.org/10.1038/s41375-022-01618-w

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark